Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
Maple Leaf Foods' outlook comes as it sees 2025 as a year of strategic transformation and financial progress, Chief Executive Curtis Frank said. "Maple Leaf Foods has demonstrated its ability to ...